http://ift.tt/1sHX1gh
Merck will release its Q3 2014 earnings on October 27th. While we expect a continued decline in legacy products, revenues from its diabetes, drugs as well as anti-infective medicines and Remicade, will continue to grow. The story for Merck is simple. The company, like many other big pharmaceutical firms, is battling revenue growth due to the loss of patent exclusivity for its key drugs. As a result, it is pegging its future hopes on developing therapeutic agents for cancer- and hepatitis C-related markets. Meanwhile, its drugs catering to immunology, diabetes and infectious diseases continue to carry it along.
from Forbes Real Time http://onforb.es/1siaXat
Merck will release its Q3 2014 earnings on October 27th. While we expect a continued decline in legacy products, revenues from its diabetes, drugs as well as anti-infective medicines and Remicade, will continue to grow. The story for Merck is simple. The company, like many other big pharmaceutical firms, is battling revenue growth due to the loss of patent exclusivity for its key drugs. As a result, it is pegging its future hopes on developing therapeutic agents for cancer- and hepatitis C-related markets. Meanwhile, its drugs catering to immunology, diabetes and infectious diseases continue to carry it along.
from Forbes Real Time http://onforb.es/1siaXat
